- Investing Ideas
- Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
8
Companies with a Value score of at least 3, ordered by Value score
8 companies
Selvita
Market Cap: zł521.3m
Provides drug discovery, drug development, and contract testing services in Poland.
SLV
zł28.40
7D
0%
1Y
-13.4%
Bayer
Market Cap: zł48.3b
Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
BAY
zł212.40
7D
-0.8%
1Y
79.2%
Genomed Spólka Akcyjna
Market Cap: zł39.4m
Provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland.
GEN
zł29.80
7D
-0.7%
1Y
15.5%
Novo Nordisk
Market Cap: zł1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NVO
zł174.12
7D
1.8%
1Y
-12.4%
Biogened
Market Cap: zł48.1m
Produces and sells cosmetics and toiletries in Poland.
BGD
zł19.60
7D
-2.0%
1Y
-26.9%
Celon Pharma
Market Cap: zł1.1b
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products.
CLN
zł20.45
7D
-1.4%
1Y
-11.3%
Eli Lilly
Market Cap: zł1.1t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LILY
zł4,498.00
7D
0%
1Y
n/a
Ryvu Therapeutics
Market Cap: zł429.1m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
RVU
zł18.56
7D
6.1%
1Y
-38.1%